Signature Financial Management Inc. bought a new stake in shares of Shire PLC (NASDAQ:SHPG) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,898 shares of the biopharmaceutical company’s stock, valued at approximately $258,000.
Other hedge funds have also added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC boosted its position in Shire by 81.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares during the period. BB&T Investment Services Inc. boosted its position in Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 786 shares during the period. Pacer Advisors Inc. purchased a new stake in Shire during the 2nd quarter valued at $171,000. Stephens Inc. AR boosted its position in Shire by 22.2% during the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares during the period. Finally, Ingalls & Snyder LLC boosted its position in Shire by 10.8% during the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 125 shares during the period. 20.28% of the stock is currently owned by institutional investors.
Shire PLC (NASDAQ SHPG) opened at $148.25 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. The stock has a market cap of $44,538.30, a PE ratio of 10.20, a P/E/G ratio of 0.82 and a beta of 1.59. Shire PLC has a 12 month low of $137.17 and a 12 month high of $192.15.
Several equities research analysts have weighed in on SHPG shares. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Jefferies Group reissued a “hold” rating and set a $206.00 price target (down previously from $216.00) on shares of Shire in a research report on Wednesday, August 9th. Barclays cut shares of Shire from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Tuesday, August 15th. Finally, Evercore ISI initiated coverage on shares of Shire in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $212.18.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/04/signature-financial-management-inc-buys-shares-of-1898-shire-plc-shpg.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.